Investing.com -- Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer’s disease (AD). The data indicated safety, tolerability, and pharmacokinetic and pharmacodynamic profiles that support further development of VG-3927 as a once-daily oral therapy for AD.
The Watertown, Massachusetts-based biotechnology firm announced the positive outcome on January 23, 2025, highlighting that the trial achieved robust and dose-dependent reductions of sTREM2, demonstrating sustained functional target engagement. The trial included various cohorts, assessing the drug’s safety and tolerability across 115 participants. Notably, no serious adverse events were reported, and all related adverse events were mild or moderate in severity.
The company is preparing to advance VG-3927 into a Phase 2 trial in the third quarter of 2025, selecting a 25mg once-daily oral dose that fully engages the desired pharmacology. Vigil Neuroscience’s President and CEO, Ivana Magovčević-Liebisch, Ph.D., J.D., expressed enthusiasm for the Phase 1 data, stating that VG-3927 has the potential to provide a more convenient treatment regimen for AD, addressing disease progression beyond targeting amyloid plaques.
The trial’s key takeaways included a favorable safety profile, high brain penetration, predictable pharmacokinetics supporting once-daily dosing, and consistent pharmacodynamics across healthy volunteers and AD patients, including various genetic variants. The company plans to present additional data at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Disease.
Vigil Neuroscience focuses on developing treatments for neurodegenerative diseases by targeting microglia, the brain’s immune cells. VG-3927 is designed to enhance microglial responses without increasing inflammation, potentially offering greater neuroprotection compared to antibody TREM2 agonists. The company is also developing other treatments, including its lead clinical candidate iluzanebart for a rare neurodegenerative disease.
The stock movement reflects investor optimism based on the reported trial results and the company’s plans for advancing VG-3927 into later-stage clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.